

AMENDMENTS TO THE CLAIMS:

The following listing of claims will replace all prior versions and listings of claims in the application:

1-37. (Cancelled)

38. (Currently Amended) A composition comprising a modified GPI molecule or derivative or equivalent thereof which induces an immune response directed to a micro-organism GPI inositolglycan domain but is incapable of inducing an immune response directed to a lipidic domain of said GPI.

39-53. (Cancelled)

54. (Currently Amended) A composition according to claim 38, wherein ~~said modified GPI molecule comprises insufficient lipidic domain to induce or elicit~~ the lipidic domain in the modified GPI molecule is incapable of inducing or eliciting an immune response directed to a GPI lipid domain.

55. (Previously Presented) A composition according to claim 38 or 54, wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

56. (Previously Presented) A composition according to claim 55, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

57. (Previously Presented) A composition according to claim 56, wherein said parasite is Plasmodium.

58. (Previously Presented) A composition according to claim 57, wherein said Plasmodium is *P. falciparum*.

59. (Previously Presented) A composition according to claim 55, wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Man α 1,2)- Man α 1,2 Man α 1,6 Man α 1,4 GlcN-myo-inositol phosphoglycerol or a derivative or equivalent thereof.

60. (Previously Presented) A composition according to claim 55, wherein said GPI inositolglycan domain comprises the structure

X1-X2-X3-X4-ethanolamine-phosphate-(Man α 1,2)-Man α 1,2Man α 1,6Man α 1,4GlcN-myo-inositol phosphoglycerol

wherein X1, X2, X3 and X4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

61. (Previously Presented) A composition according to claim 55, wherein said GPI inositolglycan domain comprises the structure

EtN-P-[M α 2]M α 2 M α 6 M α 4G α 6Ino

EtN-P-[M α 2][G]M α 2 M α 6 M α 4G α 6Ino

EtN-P-[M α 2][X]M α 2M α 6M α 4G α 6Ino

EtN-P-[M α 2][EtN-P]M α 2M α 6 M α 4G α 6Ino

EtN-P-M α 2 M α 6 M α 4G

M α 2 M α 6 M α G

EtN-P-M α 2 M α 6 M

EtN-P-[M α 2][G]M α 2 M α 6 M α 4G

EtN-P-[M α 2][X]M α 2 M α 6 M α 4G

EtN-P-[M α 2][EtN-P]M α 2 M α 6 M α 4G

M α 2 [M α 2][G]M α 2 M α 6 M α 4G

M α 2 [M α 2][X]M α 2 M α 6 M α 4G

M α 2 [M α 2][EtN-P]M α 6 M α 4G

M α 6 M α 4G α 6Ino

M α 2 M α 6 M α 4G α 6Ino

M α 2 [M α 2]M α 6 M α 4G α 6Ino

M α 2 [M α 2][G]M α 6 M α 4G α 6Ino

M α 2 [M α 2][X]M α 6 M α 4G α 6Ino

EtN-P-[M α 2][G]M α 2 M α 6 M

EtN-P-[M α 2][X]M α 2 M α 6 M

EtN-P-[M α 2][EtN-P]M α 2 M α 6 M

M α 2 [M α 2][G]M α 2 M α 6 M

M α 2 [M α 2][X]M α 2 M α 6 M

M α 2 [M α 2][EtN-P]M α 6 M

M α 2 M α 6 M

M α 6 M α 4G

EtN-P-[M α 2] [G]M α 2 M

EtN-P-[M α 2][X]M α 2 M

EtN-P-[M α 2][EtN-P]M α 2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substitute, α represent α -linkages which may be substituted with β -linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.